Here are the 10-K annual reports from Travere Therapeutics, Inc. (TVTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics files its annual report describing a rare‑disease focused biopharma business built around FILSPARI and a growing pipeline. The company now has full FDA approval for FILSPARI to slow kidney function decline in adults with IgA nephropathy and is pursuing an additional indication in focal segmental glomerulosclerosis, with a supplemental application under FDA review and an April 13, 2026 PDUFA date.
Travere is also advancing pegtibatinase in a pivotal Phase 3 trial for classical homocystinuria after resolving manufacturing scale‑up issues and restarting enrollment in 2026. Existing revenue comes from rare kidney and metabolic products, including Thiola/Thiola EC, though these face generic competition. Globally, Travere relies on partners CSL Vifor and Chugai for FILSPARI commercialization outside the United States and highlights extensive patent and orphan‑drug exclusivity intended to protect key assets.